<DOC>
	<DOCNO>NCT00404508</DOCNO>
	<brief_summary>Chemotherapy resistance , either innate acquire require development , expression change large number gene therefore , hypothesize epigenetic-mediated change could responsible drive force chemotherapy resistance . Aberrant DNA methylation histone deacetylation main epigenetic alteration hence , reversal inhibitor DNA methylation histone deacetylases ( HDACs ) may overcome resistance refractory solid tumor . Patients treat hydralazine magnesium valproate start day -7 chemotherapy end consist pre-study protocol regimen patient progress . Response toxicity evaluate . Global DNA methylation HDAC activity evaluate peripheral blood cell , well plasma level valproic acid hydralazine .</brief_summary>
	<brief_title>A Phase II Study Epigenetic Therapy Overcome Chemotherapy Resistance Refractory Solid Tumors</brief_title>
	<detailed_description>Eligible patient sign informed consent undergo study evaluation acetylation status type treat . Patients begin treatment ( day -7 ) daily dose slow-release formulation hydralazine tablet contain either 182 mg rapid-acetylators 83 mg slow-acetylators slow-release tablet contain 700mg magnesium valproate dose 40mg/Kb t.i.d . Both hydralazine magnesium valproate administer day -7 last day last chemotherapy cycle . Chemotherapy initiate day 1 ( seven day take hydralazine magnesium valproate ) pre-study protocol regimen patient show tumor progression . Toxicity evaluate course chemotherapy . Response evaluate third course chemotherapy . Promoter select gene evaluate methylation-specific PCR serum DNA 7 day treatment hydralazine valproate .</detailed_description>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<criteria>Aged18 year older . Histologically proven malignant solid tumor receive second , third fourth line palliative chemotherapy show second third course progressive disease maximum response accord RECIST criterion IGCG CA125 criterion case ovarian cancer patient . Measurable disease define 1 follow criterion : Any unidimensional measurable lesion ≥ 10 mm standard MRI CT scan solid tumor ; least 1 nonmeasurable lesion evaluable nuclear medicine , tumor marker , reliable measure . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤2 ; Absolute leukocyte count ( ≥4000/mm3 ) , platelet ≥100,000/mm3 , hemoglobin ≥9.0 g/dL ; total bilirubin , aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) &lt; 1.5 upper normal limit ( UNL ) , creatinine ≤1.2 mg/dL calculate creatinine clearance ≥60 mL/min . Life expectancy three month , Written inform consent . History allergy hydralazine valproate . Past present condition rheumatic disease , central nervous system disease , heart failure aortic stenosis postural hypotension diagnose physician . Previous use experimental drug ( hydralazine magnesium valproate ) Pregnancy breastfeed . Uncontrolled systemic disease infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Hydralazine</keyword>
	<keyword>Magnesium Valproate</keyword>
	<keyword>Chemotherapy resistance</keyword>
	<keyword>Epigenetic therapy</keyword>
</DOC>